For: | Neureiter D, Stintzing S, Kiesslich T, Ocker M. Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets. World J Gastroenterol 2019; 25(25): 3136-3150 [PMID: 31333307 DOI: 10.3748/wjg.v25.i25.3136] |
---|---|
URL: | https://www.wjgnet.com/1949-8454/full/v25/i25/3136.htm |
Number | Citing Articles |
1 |
Matthias Ocker, Daniel Neureiter. Predicting the outcome of patients with hepatocellular carcinoma: new approaches beyond established clinical scoring systems. Expert Review of Gastroenterology & Hepatology 2021; 15(2): 111 doi: 10.1080/17474124.2021.1829472
|
2 |
Xin Qing, Wenjing Xu, Jingjing Zong, Xuanlong Du, Hao Peng, Yewei Zhang. Emerging treatment modalities for systemic therapy in hepatocellular carcinoma. Biomarker Research 2021; 9(1) doi: 10.1186/s40364-021-00319-3
|
3 |
Dino Bekric, Maria Lina Tornesello, Matthias Ocker, Christian Mayr, Tobias Kiesslich, Daniel Neureiter. Editorial: Novel therapeutic approaches for biliary tract cancer and hepatocellular carcinoma. Frontiers in Cell and Developmental Biology 2023; 11 doi: 10.3389/fcell.2023.1320084
|
4 |
Malwina Sosnowska, Marta Kutwin, Barbara Strojny, Mateusz Wierzbicki, Dominik Cysewski, Jarosław Szczepaniak, Mateusz Ficek, Piotr Koczoń, Sławomir Jaworski, André Chwalibog, Ewa Sawosz. Diamond Nanofilm Normalizes Proliferation and Metabolism in Liver Cancer Cells. Nanotechnology, Science and Applications 2021; : 115 doi: 10.2147/NSA.S322766
|
5 |
Aiqing Ma, Rui Zhang. <p>Diosmetin Inhibits Cell Proliferation, Induces Cell Apoptosis and Cell Cycle Arrest in Liver Cancer</p>. Cancer Management and Research 2020; : 3537 doi: 10.2147/CMAR.S240064
|
6 |
Hong Zhao, Yujie Wang, Yufeng Liu, Xiaohua Hao, Hongshan Wei, Wen Xie. The Effect of Protein FAM172A on Proliferation in HepG2 Cells and Investigation of the Possible Molecular Mechanism. Analytical Cellular Pathology 2019; 2019: 1 doi: 10.1155/2019/5901083
|
7 |
Yinjiang Zhang, Hongyun Wei, Lu Fan, Mingyan Fang, Xu He, Binan Lu, Zongran Pang. CLEC4s as Potential Therapeutic Targets in Hepatocellular Carcinoma Microenvironment. Frontiers in Cell and Developmental Biology 2021; 9 doi: 10.3389/fcell.2021.681372
|
8 |
Chengpeng Yu, Dean Rao, He Zhu, Qiumeng Liu, Wenjie Huang, Long Zhang, Huifang Liang, Jia Song, Zeyang Ding, Gitana Maria Aceto. TDO2 Was Downregulated in Hepatocellular Carcinoma and Inhibited Cell Proliferation by Upregulating the Expression of p21 and p27. BioMed Research International 2021; 2021: 1 doi: 10.1155/2021/4708439
|
9 |
SunilGowda Sunnaghatta Nagaraja, Umadevi Subramanian, Devipriya Nagarajan. Radiation-induced H3K9 methylation on E-cadherin promoter mediated by ROS/Snail axis : Role of G9a signaling during lung epithelial-mesenchymal transition. Toxicology in Vitro 2021; 70: 105037 doi: 10.1016/j.tiv.2020.105037
|
10 |
Bart Vanderborght, Kevin De Muynck, Sander Lefere, Anja Geerts, Helena Degroote, Xavier Verhelst, Hans Van Vlierberghe, Lindsey Devisscher. Effect of isoform-specific HIF-1α and HIF-2α antisense oligonucleotides on tumorigenesis, inflammation and fibrosis in a hepatocellular carcinoma mouse model. Oncotarget 2020; 11(48): 4504 doi: 10.18632/oncotarget.27830
|
11 |
Hara Afaloniati, Katerina Angelopoulou, Alexander Giakoustidis, Alexandros Hardas, Athanasios Pseftogas, Kali Makedou, Athanasios Gargavanis, Thomas Goulopoulos, Stavros Iliadis, Vasileios Papadopoulos, Apostolos Papalois, George Mosialos, Theofilos Poutahidis, Dimitrios Giakoustidis. <p>HDAC1/2 Inhibitor Romidepsin Suppresses DEN-Induced Hepatocellular Carcinogenesis in Mice</p>. OncoTargets and Therapy 2020; : 5575 doi: 10.2147/OTT.S250233
|
12 |
Matthias Ocker, Christian Mayr, Tobias Kiesslich, Sebastian Stintzing, Daniel Neureiter. Immunmodulatory Treatment Strategies of Hepatocellular Carcinoma: From Checkpoint Inhibitors Now to an Integrated Approach in the Future. Cancers 2021; 13(7): 1558 doi: 10.3390/cancers13071558
|
13 |
Sulaiman S. Alhudaithi, Mohd Abul Kalam, Lama Binobaid, Raisuddin Ali, Mohammed M. Almutairi, Wajhul Qamar, Hessa Bin Hithlayn, Atheer Almutairi, Abdullah K. Alshememry. Sorafenib and Piperine co-loaded PLGA nanoparticles: Development, characterization, and anti-cancer activity against hepatocellular carcinoma cell line. Saudi Pharmaceutical Journal 2024; 32(5): 102064 doi: 10.1016/j.jsps.2024.102064
|
14 |
Tao Wang, Zhiying Hou, Xinyuan Chen, Li Zhao, Deqi Zhu, Ning Wang, Yufen Zhao, Bin Zhang. Analysis of the medication rules of traditional Chinese medicines (TCMs) in treating liver cancer and potential TCMs exploration. Pharmacological Research - Modern Chinese Medicine 2022; 3: 100086 doi: 10.1016/j.prmcm.2022.100086
|
15 |
Leandro Ryuchi Iuamoto, Alberto Meyer. Commentary on "The risk factors for long-term survival outcome in solitary hepatocellular carcinoma up to 2 cm: Propensity score matching analysis in a population cohort with a high rate of HBV infection". International Journal of Surgery 2019; 72: 144 doi: 10.1016/j.ijsu.2019.10.045
|
16 |
Abdullah Al Mamun, Yanqing Wu, Chang Jia, Fahad Munir, Kasfia Jahan Sathy, Tamanna Sarker, Ilma Monalisa, Kailiang Zhou, Jian Xiao. Role of pyroptosis in liver diseases. International Immunopharmacology 2020; 84: 106489 doi: 10.1016/j.intimp.2020.106489
|
17 |
Baozhu Zhang, Qing Zhou, Qiankun Xie, Xiaohui Lin, Wenqiang Miao, Zhaoguang Wei, Tingting Zheng, Zuoliang Pang, Haosheng Liu, Xi Chen. SPC25 overexpression promotes tumor proliferation and is prognostic of poor survival in hepatocellular carcinoma. Aging 2021; 13(2): 2803 doi: 10.18632/aging.202329
|
18 |
Ziwei Guo, Ziang Yao, Bohao Huang, Dongjie Wu, Yanbo Li, Xiaohan Chen, Yanping Lu, Li Wang, Wenliang Lv. MAFLD-related hepatocellular carcinoma: Exploring the potent combination of immunotherapy and molecular targeted therapy. International Immunopharmacology 2024; 140: 112821 doi: 10.1016/j.intimp.2024.112821
|
19 |
Christoph Roderburg, Alexander Wree, Münevver Demir, Moritz Schmelzle, Frank Tacke. The role of the innate immune system in the development and treatment of hepatocellular carcinoma. Hepatic Oncology 2020; 7(1) doi: 10.2217/hep-2019-0007
|
20 |
Shengkui Tan, Xuefeng Guo, Chunhua Bei, Huixia Zhang, Di Li, Xiaonian Zhu, Hongzhuan Tan. Prognostic significance and immune characteristics of CMTM4 in hepatocellular carcinoma. BMC Cancer 2022; 22(1) doi: 10.1186/s12885-022-09999-y
|
21 |
Mindan Xing, Jia Li. Diagnostic and prognostic values of pyroptosis-related genes for the hepatocellular carcinoma. BMC Bioinformatics 2022; 23(1) doi: 10.1186/s12859-022-04726-7
|
22 |
Sarah B. White, Dilip Rajasekhar Maddirela. Hepatobiliary Cancers: An Interdisciplinary Approach. Interdisciplinary Cancer Research 2023; 3: 255 doi: 10.1007/16833_2022_122
|
23 |
Srinivas Reddy Pallerla, Nghiem Xuan Hoan, Sivaramakrishna Rachakonda, Christian G. Meyer, Hoang Van Tong, Nguyen Linh Toan, Le Thi Kieu Linh, Dao Phuong Giang, Peter G. Kremsner, Mai Hong Bang, Le Huu Song, Thirumalaisamy P. Velavan. Custom gene expression panel for evaluation of potential molecular markers in hepatocellular carcinoma. BMC Medical Genomics 2022; 15(1) doi: 10.1186/s12920-022-01386-7
|
24 |
S. Yao, K. Prates, A. Freydenzon, G. Assante, A. F. McRae, M. J. Morris, N. A. Youngson. Liver‐specific deletion of de novo DNA methyltransferases protects against glucose intolerance in high‐fat diet‐fed male mice. The FASEB Journal 2024; 38(10) doi: 10.1096/fj.202301546RR
|
25 |
Xiaoming Dai, Ruixue Huang, Sai Hu, Yao Zhou, Xiaoya Sun, Pucheng Gui, Zijian Yu, Pingkun Zhou. A novel miR-0308-3p revealed by miRNA-seq of HBV-positive hepatocellular carcinoma suppresses cell proliferation and promotes G1/S arrest by targeting double CDK6/Cyclin D1 genes. Cell & Bioscience 2020; 10(1) doi: 10.1186/s13578-020-00382-7
|
26 |
Bart Vanderborght, Sander Lefere, Hans Van Vlierberghe, Lindsey Devisscher. The Angiopoietin/Tie2 Pathway in Hepatocellular Carcinoma. Cells 2020; 9(11): 2382 doi: 10.3390/cells9112382
|
27 |
Alexandru Blidisel, Iasmina Marcovici, Dorina Coricovac, Florin Hut, Cristina Adriana Dehelean, Octavian Marius Cretu. Experimental Models of Hepatocellular Carcinoma—A Preclinical Perspective. Cancers 2021; 13(15): 3651 doi: 10.3390/cancers13153651
|
28 |
Hara Afaloniati, Theofilos Poutahidis, Alexander Giakoustidis, Athanasios Gargavanis, Dimitrios Giakoustidis, Katerina Angelopoulou. Romidepsin hepatocellular carcinoma suppression in mice is associated with deregulated gene expression of bone morphogenetic protein and Notch signaling pathway components. Molecular Biology Reports 2021; 48(1): 551 doi: 10.1007/s11033-020-06089-9
|
29 |
Ruoyu Guo, Jixia Li, Jinxia Hu, Qiang Fu, Yunfei Yan, Sen Xu, Xin Wang, Fei Jiao. Combination of epidrugs with immune checkpoint inhibitors in cancer immunotherapy: From theory to therapy. International Immunopharmacology 2023; 120: 110417 doi: 10.1016/j.intimp.2023.110417
|
30 |
Nurbubu T. Moldogazieva, Sergey P. Zavadskiy, Susanna S. Sologova, Innokenty M. Mokhosoev, Alexander A. Terentiev. Predictive biomarkers for systemic therapy of hepatocellular carcinoma. Expert Review of Molecular Diagnostics 2021; 21(11): 1147 doi: 10.1080/14737159.2021.1987217
|
31 |
Zahra Heidari, Azam Asemi-Rad, Bita Moudi, Hamidreza Mahmoudzadeh-Sagheb. mRNA expression and epigenetic-based role of chromodomain helicase DNA-binding 5 in hepatocellular carcinoma. Journal of International Medical Research 2022; 50(7): 030006052211053 doi: 10.1177/03000605221105344
|
32 |
MicroRNA-483-5p Inhibits Hepatocellular Carcinoma Cell Proliferation, Cell Steatosis, and Fibrosis by Targeting PPARα and TIMP2. Cancers 2023; 15(6): 1715 doi: 10.3390/cancers15061715
|
33 |
Aiyao Wang, Jun Meng, Hui Liu, Chen Li, Zhiyong Zhou. Long non‑coding RNA BCAR4 promotes liver cancer progression by regulating proliferation, migration and invasion. Oncology Letters 2020; 20(3): 2779 doi: 10.3892/ol.2020.11826
|
34 |
Kurt Sartorius, Ping An, Cheryl Winkler, Anil Chuturgoon, Xiaodong Li, Julia Makarova, Anna Kramvis. The Epigenetic Modulation of Cancer and Immune Pathways in Hepatitis B Virus-Associated Hepatocellular Carcinoma: The Influence of HBx and miRNA Dysregulation. Frontiers in Immunology 2021; 12 doi: 10.3389/fimmu.2021.661204
|
35 |
Gang Wang, Xuefeng Li, Hongyan Jia, Lei Zhang, Yang Li, Qiuxue Zhang, Meng Lu. Curcumin nanocarrier carrying si-TAR-RNA binding protein (TRBP) restricts development of hepatocellular carcinoma. Materials Express 2023; 13(3): 407 doi: 10.1166/mex.2023.2368
|
36 |
Prithvi Singh, Rubi Solanki, Alvea Tasneem, Simran Suri, Harleen Kaur, Sapna Ratan Shah, Ravins Dohare. Screening of miRNAs as prognostic biomarkers and their associated hub targets across Hepatocellular carcinoma using survival-based bioinformatics approach. Journal of Genetic Engineering and Biotechnology 2024; 22(1): 100337 doi: 10.1016/j.jgeb.2023.100337
|
37 |
Matthew R. Woeste, Anne E. Geller, Robert C. G. Martin, Hiram C. Polk. Optimizing the Combination of Immunotherapy and Trans-Arterial Locoregional Therapy for Stages B and C Hepatocellular Cancer. Annals of Surgical Oncology 2021; 28(3): 1499 doi: 10.1245/s10434-020-09414-5
|
38 |
AM Kabel, HH Arab, MA Abd Elmaaboud. Attenuation of diethyl nitrosamine-induced hepatocellular carcinoma by taxifolin and/or alogliptin: The interplay between toll-like receptor 4, transforming growth factor beta-1, and apoptosis. Human & Experimental Toxicology 2021; 40(10): 1710 doi: 10.1177/09603271211008496
|
39 |
Payal Deepak, Rajinikanth Siddalingam, Praveen Kumar, Sneha Anand, Sunita Thakur, Balasubramaniam Jagdish, Shweta Jaiswal. Gene based nanocarrier delivery for the treatment of hepatocellular carcinoma. Journal of Drug Delivery Science and Technology 2020; 59: 101837 doi: 10.1016/j.jddst.2020.101837
|
40 |
Dino Bekric, Matthias Ocker, Christian Mayr, Sebastian Stintzing, Markus Ritter, Tobias Kiesslich, Daniel Neureiter. Ferroptosis in Hepatocellular Carcinoma: Mechanisms, Drug Targets and Approaches to Clinical Translation. Cancers 2022; 14(7): 1826 doi: 10.3390/cancers14071826
|
41 |
C. Lv, X. J. Li, L. X. Hao, S. Zhang, Z. Song, X. D. Ji, B. Gong. Over-activation of EFTUD2 correlates with tumor propagation and poor survival outcomes in hepatocellular carcinoma. Clinical and Translational Oncology 2022; 24(1): 93 doi: 10.1007/s12094-021-02673-y
|
42 |
Prashika Singh, Dylan Kairuz, Patrick Arbuthnot, Kristie Bloom. Silencing hepatitis B virus covalently closed circular DNA: The potential of an epigenetic therapy approach. World Journal of Gastroenterology 2021; 27(23): 3182-3207 doi: 10.3748/wjg.v27.i23.3182
|
43 |
Yu Jiang, Lijuan Lin, Huiming Lv, He Zhang, Lili Jiang, Fenfen Ma, Qiuyue Wang, Xue Ma, Shengjin Yu. Immune cell infiltration and immunotherapy in hepatocellular carcinoma. Mathematical Biosciences and Engineering 2022; 19(7): 7178 doi: 10.3934/mbe.2022339
|
44 |
Meng Cheng, Qingmiao Yang, Yafei Liu, Meng-Jie Zhao, Xinyuan Du, Jiaqi Sun, Wen-Jie Shu, Zan Huang, Jianping Bi, Ximing Xu, Hai-Ning Du. SETD3 Methyltransferase Regulates PLK1 Expression to Promote In Situ Hepatic Carcinogenesis. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.882202
|
45 |
Eckhard Klieser, Christian Mayr, Tobias Kiesslich, Till Wissniowski, Pietro Di Fazio, Daniel Neureiter, Matthias Ocker. The Crosstalk of miRNA and Oxidative Stress in the Liver: From Physiology to Pathology and Clinical Implications. International Journal of Molecular Sciences 2019; 20(21): 5266 doi: 10.3390/ijms20215266
|
46 |
Gianluca Cassese, Ho-Seong Han, Boram Lee, Hae Won Lee, Jai Young Cho, Fabrizio Panaro, Roberto Ivan Troisi. Immunotherapy for hepatocellular carcinoma: A promising therapeutic option for advanced disease. World Journal of Hepatology 2022; 14(10): 1862-1874 doi: 10.4254/wjh.v14.i10.1862
|